Drug intelligence / Profile preview

ALVAC NY ESO-1

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

ALVAC NY ESO-1 is a cancer vaccine designed to stimulate the immune system to recognize and attack tumor cells expressing the cancer-testis antigen NY-ESO-1. The vaccine uses a recombinant canarypox virus (ALVAC) as a vector to deliver the gene encoding the full-length NY-ESO-1 protein. Upon administration, it aims to induce a cytotoxic T lymphocyte (CTL) response against cancer cells that express NY-ESO-1, potentially inhibiting tumor growth and proliferation. This approach leverages both cellular and humoral immunity for antitumor effects. The primary indications under investigation include metastatic melanoma and renal cell carcinoma[1][6].

Other names: ALVAC NY ESO-1 vaccineALVAC ESO-1 vaccine

Targets

MHC-NY-ESO-1 (Major Histocompatibility Complex-NY-ESO-1 peptide complex)

Beyond the preview

Go deeper on ALVAC NY ESO-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALVAC NY ESO-1.

Explore the full profile